CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

Stock Information for Cocrystal Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cocrystal Pharma Inc.

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
CASI Pharmaceuticals Provides Business and Clinical Update
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.